Hsbc Holdings PLC Has $2.75 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Hsbc Holdings PLC lifted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPTFree Report) by 1,033.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 28,513 shares of the biotechnology company’s stock after acquiring an additional 25,998 shares during the quarter. Hsbc Holdings PLC’s holdings in Sarepta Therapeutics were worth $2,750,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Montag A & Associates Inc. acquired a new stake in shares of Sarepta Therapeutics in the third quarter valued at about $30,000. Cary Street Partners Investment Advisory LLC increased its position in shares of Sarepta Therapeutics by 154.0% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 154 shares during the last quarter. Principal Securities Inc. bought a new position in Sarepta Therapeutics during the fourth quarter worth about $26,000. CWM LLC grew its holdings in Sarepta Therapeutics by 178.7% during the fourth quarter. CWM LLC now owns 577 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 370 shares during the period. Finally, Fifth Third Bancorp grew its holdings in Sarepta Therapeutics by 1,215.8% during the fourth quarter. Fifth Third Bancorp now owns 1,000 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 924 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Insider Activity at Sarepta Therapeutics

In related news, insider Dallan Murray sold 3,635 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total value of $508,900.00. Following the completion of the sale, the insider now directly owns 18,125 shares in the company, valued at $2,537,500. The sale was disclosed in a filing with the SEC, which is available at this link. In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 761 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the completion of the transaction, the director now directly owns 7,516 shares in the company, valued at $923,941.88. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Dallan Murray sold 3,635 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total transaction of $508,900.00. Following the transaction, the insider now owns 18,125 shares of the company’s stock, valued at $2,537,500. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms recently commented on SRPT. Royal Bank of Canada reiterated a “sector perform” rating and set a $142.00 price target (down previously from $157.00) on shares of Sarepta Therapeutics in a report on Tuesday, May 28th. Piper Sandler began coverage on Sarepta Therapeutics in a report on Friday, May 31st. They set an “overweight” rating and a $157.00 price target for the company. UBS Group lifted their price target on Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Wedbush reiterated an “outperform” rating and set a $224.00 price target on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Finally, Evercore ISI lifted their price target on Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an “in-line” rating in a report on Tuesday, February 20th. Four investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $164.00.

View Our Latest Stock Report on SRPT

Sarepta Therapeutics Trading Down 2.0 %

Shares of SRPT stock opened at $117.44 on Friday. The company has a current ratio of 4.05, a quick ratio of 3.44 and a debt-to-equity ratio of 1.18. The stock has a market cap of $11.10 billion, a P/E ratio of 1,067.64 and a beta of 0.96. The stock has a 50 day simple moving average of $125.95 and a 200 day simple moving average of $116.56. Sarepta Therapeutics, Inc. has a 1 year low of $55.25 and a 1 year high of $146.68.

Sarepta Therapeutics (NASDAQ:SRPTGet Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.84. The business had revenue of $413.50 million during the quarter, compared to analysts’ expectations of $375.52 million. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The firm’s revenue for the quarter was up 63.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.44) earnings per share. On average, research analysts predict that Sarepta Therapeutics, Inc. will post 2.99 earnings per share for the current fiscal year.

Sarepta Therapeutics Company Profile

(Free Report)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Recommended Stories

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPTFree Report).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.